Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOLD-100 + FOLFOX ± Bevacizumab in Advanced Solid Tumours
NCT04421820Phase 2Recruiting
- Sponsor
- Bold Therapeutics
- Start
- Aug 2020
- Primary completion
- Jul 2027
- Modality
- DNA Intercalators/Alkylators, Covalent Small Molecules, Light/Condition-Responsive Prodrugs
- Countries
- 8
01
Overview
A Phase 2 trial of BOLD-100 in colorectal cancer (CRC), pancreatic cancer (PC), gastric cancer (GC), cholangiocarcinoma (CCA), sponsored by Bold Therapeutics. Started Aug 2020; status: recruiting.
02
Drugs
BOLD-100
03
Conditions
colorectal cancer (CRC)pancreatic cancer (PC)gastric cancer (GC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT04421820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04421820.